-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: biotech industry
My family farm isn’t under “corporate control”
On CNN’s blog, “Eatocracy”, Indiana farmer Brian Scott challenges the myth that farmers are slaves to “Big Ag” and explains from first-hand experience how biotech seed contracts work. In his blog post titled, “My family farm isn’t under ‘corporate control’“, Scott posts a copy of an actual technology agreement he signed, and explains how such agreements help him to operate the farm in the manner his family chooses. Among the requirements of technology and stewardship Read More >
What’s Behind the Rise in Executive Liability Insurance Prices?
What do gas, milk, bacon, electricity and now your Directors and Officers Liability Insurance coverage have in common? It may sound like the start of a bad joke but, in fact, they’re all goods or services that cost more than they used to. Some of you may have noticed that the price of Directors and Officers Liability, or D&O Insurance, is going up. Companies and organizations across the biotechnology sector are seeing price increases, with Read More >
Anti-Biotech Activist Changes Sides: “I discovered science”
If you missed last week’s report from the Oxford Farming Conference, Mark Lynas, the British writer and environmentalist who once helped drive Europe’s movement against biotech crops, apologized for those actions and embraced the technology as a vital tool for ending hunger and conserving the environment. The change of heart was widely reported in many mainstream outlets such as The New York Times, Los Angeles Times, Forbes, Discover magazine, Slate magazine and Science 2.0, among others. Read More >
Harder, Better, Faster, Stronger: Takeaways from Partnering For Cures 2012
The chorus to Kanye West’s 2007 chart-topper Stronger can teach us volumes about speeding drug development. Harder: Drug development is challenging. It takes over 10 years and more than $1 billon to bring a therapy through the product pipeline, from the research lab to clinical trials to FDA approval to prescription to patients suffering from the disease. The FDA approved over 30 innovative drugs last year, including more than 10 new treatments for cancer—a good Read More >
Small Companies, Big Returns
The broader biotech indices are up more than 30 percent this year and have reached levels not seen since the peak of March 2000. Larger biotechs account for much of the index returns, as we have described previously, and have helped the sector outperform the S&P 500 by two fold. But how have smaller biotech companies been performing? As of Nov 30, 27 companies that started the year under $1 billion in market capitalization have Read More >
